← Eichor
Study identifier: NCT07169825 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

Condition: Lu-177 PSMA  ·  Sponsor: M.D. Anderson Cancer Center

PhaseNA
Planned participants25
Who can joinMale, N/A to no upper limit
Healthy volunteersNo

About this study

To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.

This description comes directly from the study's public registry record.

Talk to the study team

Guofan Xu, MD  ·  713-745-9017  ·  gxu2@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07169825